Company Overview of Novo Nordisk, Inc.
Novo Nordisk, Inc. operates as a healthcare company that focuses on diabetes care. The company provides diabetes pharmaceuticals and insulin delivery systems. It also specializes in hemophilia care, growth hormone therapy, and hormone replacement therapy. The company was incorporated in 1982 and is headquartered in Princeton, New Jersey. It has a manufacturing facility in Clayton, North Carolina; and a research and development center in Seattle, Washington. Novo Nordisk, Inc. operates as a subsidiary of Novo Nordisk A/S.
100 College Road West
Princeton, NJ 08540
Founded in 1982
Key Executives for Novo Nordisk, Inc.
Senior Vice President of Finance and Operations
Chief Executive Officer of Novo Nordisk A/S and President of Novo Nordisk A/S
Corporate Vice President and General Counsel
Chief Compliance Officer and Vice President of Compliance
Compensation as of Fiscal Year 2014.
Novo Nordisk, Inc. Key Developments
Novo Nordisk, Inc. Presents at 7th annual Biotech Showcase Conference 2015, Jan-12-2015
Dec 24 14
Novo Nordisk, Inc. Presents at 7th annual Biotech Showcase Conference 2015, Jan-12-2015 . Venue: Parc 55 Wyndham San, Francisco - Union Square, San Francisco, CA 94102, United States.
Novo Nordisk Announces New Analysis of Phase 3 Data Demonstrating People with Haemophilia A
Dec 7 14
Novo Nordisk announced a new analysis of phase 3 data demonstrating people with haemophilia A who had the high annualised bleeding rate (ABR) during initial treatment with NovoEight (turoctocog alfa) showed the large reduction in bleeding over the duration of treatment. The post hoc analysis from the guardian 2 trial further found that, when continued on treatment with NovoEight, adults and adolescents showed reductions of 69% and 63%, respectively, in ABR compared with their ABRs from guardian 1. The guardian 1 trial (along with guardian 3) showed that NovoEight was efficacious in preventing and reducing bleeds with no confirmed inhibitor development in 213 previously treated patients. The most common adverse reactions (=0.5%) seen in the study were injection site reactions, increased hepatic enzymes, and fever.
Novo Nordisk, Inc. Appoints Jackie Scanlan as Corporate Vice President, Human Resources
Oct 15 14
Novo Nordisk Inc. announced that Jackie Scanlan joined its executive team as Corporate Vice President, Human Resources. Jackie comes to Novo Nordisk from the Campbell Soup Company, where she most recently served as vice president of human resources for its international business unit. Under her leadership, she led activities involving organizational development, change and talent management.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|